Bolt Biotherapeutics, Inc.
BOLT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.66 | 0.60 | 0.63 | -0.92 |
| FCF Yield | -15.01% | -8.23% | -8.08% | -1.62% |
| EV / EBITDA | -6.42 | -11.52 | -11.11 | -39.98 |
| Quality | ||||
| ROIC | -84.91% | -53.62% | -43.62% | -32.12% |
| Gross Margin | 100.00% | -681.39% | -1,176.37% | -5,904.37% |
| Cash Conversion Ratio | 0.97 | 1.00 | 0.87 | 0.58 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.31% | 84.21% | 191.62% | 1,079,982.30% |
| Free Cash Flow Growth | 12.05% | 11.12% | -32.07% | -17.47% |
| Safety | ||||
| Net Debt / EBITDA | -0.27 | -0.13 | -0.15 | 0.03 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 55.30 | -17.72 | -17.94 | 40.69 |